tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

XFOR Stock Latest News

X4 Pharmaceuticals price target raised to $10 from $7.50 at Stifel
The FlyX4 Pharmaceuticals price target raised to $10 from $7.50 at Stifel
20d ago
XFOR
X4 Pharmaceuticals price target raised to $5 from $3.50 at H.C. Wainwright
PremiumThe Fly
X4 Pharmaceuticals price target raised to $5 from $3.50 at H.C. Wainwright
1M ago
XFOR
X4 Pharmaceuticals Focuses on Chronic Neutropenia Trial
PremiumCompany Announcements
X4 Pharmaceuticals Focuses on Chronic Neutropenia Trial
2M ago
XFOR
X4 Pharmaceuticals price target lowered to $7.50 from $9 at Stifel
PremiumThe Fly
X4 Pharmaceuticals price target lowered to $7.50 from $9 at Stifel
2M ago
XFOR
X4 Pharmaceuticals reports Q3 EPS (69c), consensus (84c)
PremiumThe Fly
X4 Pharmaceuticals reports Q3 EPS (69c), consensus (84c)
2M ago
XFOR
X4 Pharmaceuticals 45.87M share Spot Secondary priced at $2.85
PremiumThe FlyX4 Pharmaceuticals 45.87M share Spot Secondary priced at $2.85
2M ago
XFOR
X4 Pharmaceuticals announces common stock offering, no amount given
Premium
The Fly
X4 Pharmaceuticals announces common stock offering, no amount given
2M ago
XFOR
Altimmune appoints Christophe Arbet-Engels as CMO
Premium
The Fly
Altimmune appoints Christophe Arbet-Engels as CMO
3M ago
ALT
XFOR
X4 Pharmaceuticals Announces Major Strategic Restructuring
PremiumCompany Announcements
X4 Pharmaceuticals Announces Major Strategic Restructuring
3M ago
8K
XFOR
X4 Pharmaceuticals announces restructuring, 50% reduction in workforce
PremiumThe Fly
X4 Pharmaceuticals announces restructuring, 50% reduction in workforce
3M ago
XFOR
X4 Pharmaceuticals files to sell 59.89M shares of common stock for holders
PremiumThe Fly
X4 Pharmaceuticals files to sell 59.89M shares of common stock for holders
4M ago
XFOR
X4 Pharmaceuticals price target lowered to $9 from $30 at Stifel
PremiumThe Fly
X4 Pharmaceuticals price target lowered to $9 from $30 at Stifel
4M ago
XFOR
X4 Pharmaceuticals Announces Board Resignations and Appointments
PremiumCompany AnnouncementsX4 Pharmaceuticals Announces Board Resignations and Appointments
4M ago
8K
XFOR
3 Penny Stocks to Watch Now, 8/14/25
Premium
Market News
3 Penny Stocks to Watch Now, 8/14/25
4M ago
MNTS
RSLS
X4 Pharmaceuticals Closes $85M Private Placement Deal
Premium
Company Announcements
X4 Pharmaceuticals Closes $85M Private Placement Deal
4M ago
8K
XFOR
X4 Pharmaceuticals price target lowered to $3.50 from $7 at H.C. Wainwright
PremiumThe Fly
X4 Pharmaceuticals price target lowered to $3.50 from $7 at H.C. Wainwright
4M ago
XFOR
X4 Pharmaceuticals trading halted, news pending
PremiumThe Fly
X4 Pharmaceuticals trading halted, news pending
4M ago
XFOR
X4 Pharmaceuticals Announces $60M Equity Financing
PremiumCompany Announcements
X4 Pharmaceuticals Announces $60M Equity Financing
4M ago
8K
XFOR
X4 Pharmaceuticals announces $60M financing, management changes
PremiumThe Fly
X4 Pharmaceuticals announces $60M financing, management changes
4M ago
XFOR
X4 Pharmaceuticals Advances Phase 3 Study for WHIM Syndrome Treatment
PremiumCompany AnnouncementsX4 Pharmaceuticals Advances Phase 3 Study for WHIM Syndrome Treatment
5M ago
XFOR
X4 Pharmaceuticals Advances Phase 3 Study of Mavorixafor for WHIM Syndrome
Premium
Company Announcements
X4 Pharmaceuticals Advances Phase 3 Study of Mavorixafor for WHIM Syndrome
5M ago
XFOR
X4 Pharmaceuticals Completes Key Study on Mavorixafor’s Drug Interaction Potential
Premium
Company Announcements
X4 Pharmaceuticals Completes Key Study on Mavorixafor’s Drug Interaction Potential
6M ago
XFOR

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >